Teva Foresees Sustained Growth Despite Slow Start To Fiscal 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
Generics firm expects growth from generic Pravachol and generic Zocor exclusivity periods.
You may also be interested in...
Copaxone Sales Will Continue Growth Regardless Of Tysabri Re-Launch, Teva Says
Teva expects sales of its multiple sclerosis therapy Copaxone (glatiramer)to continue to grow in 2006 regardless of whether FDA allows the re-launch of competitor Tysabri (natalizumab)
Statin Prices Likely To Remain High After Zocor Exclusivity Win
Teva and Ranbaxy appear slated for 180 days of simvastatin exclusivity after federal court ruling postponing mass generic entry into the sector until 2007.
Teva Launches Pravachol Generic; Ranbaxy Stuck At FDA
Watson also enters into the pravastatin market with an authorized generic.